Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K

Vaccine

Volumn 34, Issue 19, 2016, Pages 2179-2187

  Cha, Seung Bin ^a   Kim, Woo Sik ^a   Kim, Jong Seok ^a   Kim, Hongmin ^a   Kwon, Kee Woong ^a   Han, Seung Jung ^a   Cho, Sang Nae ^a   Coler, Rhea N ^b   Reed, Steven G ^b   Shin, Sung Jae ^a  

^a Yonsei University College of Medicine   (South Korea)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Beijing family; GLA SE; ID93; K strain; Tuberculosis

Indexed keywords

ADJUVANT; GLA SE VACCINE; ID93 VACCINE; MYCOBACTERIUM VACCINE; UNCLASSIFIED DRUG; BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; MEMORY CELL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; ANIMAL; BACTERIAL LOAD; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLASSIFICATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LUNG; MICROBIOLOGY; PATHOLOGY; SPLEEN; TUBERCULOSIS;

ANIMALS; BACTERIAL LOAD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-2; LUNG; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; SPLEEN; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84963632208     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.029     Document Type: Article

References (37)

1. Organization WH Tuberculosis fact sheet no. 104 2014, World Health Organization, Geneva, Switzerland.
2. Wu J., Dalal K. Tuberculosis in Asia and the pacific: the role of socioeconomic status and health system development. Int J Prev Med 2012, 3:8-16.
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
4. Andersen P., Doherty T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005, 3:656-662.
5. McShane H., Williams A. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis 2014, 94:105-110.
6. Orme I.M. The Achilles heel of BCG. Tuberculosis 2010, 90:329-332.
7. Jeon B.Y., Derrick S.C., Lim J., Kolibab K., Dheenadhayalan V., Yang A.L., et al. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect Immun 2008, 76:5173-5180.
8. Reiling N., Homolka S., Walter K., Brandenburg J., Niwinski L., Ernst M., et al. Clade-specific virulence patterns of Mycobacterium tuberculosis complex strains in human primary macrophages and aerogenically infected mice. MBio 2013, 4. e00250-13.
9. van Soolingen D., Qian L., de Haas P.E., Douglas J.T., Traore H., Portaels F., et al. Predominance of a single genotype of Mycobacterium tuberculosis in countries of East Asia. J Clin Microbiol 1995, 33:3234-3238.
10. Bifani P.J., Mathema B., Kurepina N.E., Kreiswirth B.N. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002, 10:45-52.
11. Glynn J.R., Whiteley J., Bifani P.J., Kremer K., van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2002, 8:843-849.
12. Wada T., Iwamoto T., Maeda S. Genetic diversity of the Mycobacterium tuberculosis Beijing family in East Asia revealed through refined population structure analysis. FEMS Microbiol Lett 2009, 291:35-43.
13. Chen Y.Y., Chang J.R., Huang W.F., Kuo S.C., Su I.J., Sun J.R., et al. Genetic diversity of the Mycobacterium tuberculosis Beijing family based on SNP and VNTR typing profiles in Asian countries. PLoS ONE 2012, 7:e39792.
14. Yang C., Luo T., Sun G., Qiao K., Sun G., DeRiemer K., et al. Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China. Clin Infect Dis 2012, 55:1179-1187. an official publication of the Infectious Diseases Society of America.
15. Parwati I., van Crevel R., van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis 2010, 10:103-111.
16. Bertholet S., Ireton G.C., Ordway D.J., Windish H.P., Pine S.O., Kahn M., et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010, 2:53ra74.
17. Baldwin S.L., Bertholet S., Reese V.A., Ching L.K., Reed S.G., Coler R.N. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 2012, 188:2189-2197.
18. Shamputa I.C., Lee J., Allix-Beguec C., Cho E.J., Lee J.I., Rajan V., et al. Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol 2010, 48:387-394.
19. Kim S.J., Bai G.H., Lee H., Kim H.J., Lew W.J., Park Y.K., et al. Transmission of Mycobacterium tuberculosis among high school students in Korea. Int J Tuberc Lung Dis 2001, 5:824-830. the official journal of the International Union against Tuberculosis and Lung Disease.
20. Kang H.Y., Wada T., Iwamoto T., Maeda S., Murase Y., Kato S., et al. Phylogeographical particularity of the Mycobacterium tuberculosis Beijing family in South Korea based on international comparison with surrounding countries. J Med Microbiol 2010, 59:1191-1197.
21. Bahk Y.Y., Kim S.A., Kim J.S., Euh H.J., Bai G.H., Cho S.N., et al. Antigens secreted from Mycobacterium tuberculosis: identification by proteomics approach and test for diagnostic marker. Proteomics 2004, 4:3299-3307.
22. Han S.J., Song T., Cho Y.J., Kim J.S., Choi S.Y., Bang H.E., et al. Complete genome sequence of Mycobacterium tuberculosis K from a Korean high school outbreak, belonging to the Beijing family. Stand Genomic Sci 2015, 10:78.
23. Jeon B.Y., Kwak J., Hahn M.Y., Eum S.Y., Yang J., Kim S.C., et al. In vivo characteristics of Korean Beijing Mycobacterium tuberculosis strain K1 in an aerosol challenge model and in the Cornell latent tuberculosis model. J Med Microbiol 2012, 61:1373-1379.
24. Kim W.S., Kim J.S., Cha S.B., Han S.J., Kim H., Kwon K.W., et al. Virulence-Dependent Alterations in the Kinetics of Immune Cells during Pulmonary Infection by Mycobacterium tuberculosis. PLoS ONE 2015, 10:e0145234.
25. Jeon B.Y., Kim S.C., Eum S.Y., Cho S.N. The immunity and protective effects of antigen 85A and heat-shock protein X against progressive tuberculosis. Microb Infect/Inst Pasteur 2011, 13:284-290.
26. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
27. Bachmann M.F., Wolint P., Schwarz K., Jager P., Oxenius A. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol 2005, 175:4686-4696.
28. Coler R.N., Bertholet S., Pine S.O., Orr M.T., Reese V., Windish H.P., et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis 2013, 207:1242-1252.
29. Orr M.T., Beebe E.A., Hudson T.E., Moon J.J., Fox C.B., Reed S.G., et al. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS ONE 2014, 9:e83884.
30. Condos R., Rom W.N., Liu Y.M., Schluger N.W. Local immune responses correlate with presentation and outcome in tuberculosis. Am J Respir Crit Care Med 1998, 157:729-735.
31. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V., Beverley P.C., et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181:4955-4964.
32. Henao-Tamayo M.I., Ordway D.J., Irwin S.M., Shang S., Shanley C., Orme I.M. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin Vaccine Immunol: CVI 2010, 17:618-625.
33. Orr M.T., Ireton G.C., Beebe E.A., Huang P.W., Reese V.A., Argilla D., et al. Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis. J Immunol 2014, 193:2911-2918.
34. Chen C.Y., Huang D., Wang R.C., Shen L., Zeng G., Yao S., et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 2009, 5:e1000392.
35. Commandeur S., Lin M.Y., van Meijgaarden K.E., Friggen A.H., Franken K.L., Drijfhout J.W., et al. Double- and monofunctional CD4(+) and CD8(+) T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol 2011, 41:2925-2936.
36. Orr M.T., Beebe E.A., T E.H., Argilla D., Huang P.W., Reese V.A., et al. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy. Vaccine 2015, 33:6570-6578.
37. Zuckerman J.N. The importance of injecting vaccines into muscle. Different patients need different needle sizes. BMJ 2000, 321:1237-1238.